Cheng G M, Karayiannis P, Thomas H C
Institute of Hepatitis, Chongqing Medical University.
Zhonghua Nei Ke Za Zhi. 1990 Mar;29(3):141-3, 188-9.
Response to interferon therapy in chronic hepatitis B virus (HBV) carrier is preceded by the appearance of IgM class anti-HBc (antibody to hepatitis B core antigen). The temporal relationship and magnitude of the IgM anti-HBc response is variable, suggesting that the antibody is not directly involved in hepatocyte lysis, but is merely a marker of a changed state of immunity to the nucleocapsid proteins induced by interferon. IgG 1, 2, 3 and 4 did not change during therapy. IgG anti-HBc of all subclasses was absent in two Chinese HBV carriers. Lower than normal titres of anti-HBc (P less than 0.001) were detected in human immunodeficiency virus antibody positive (anti-HIV) carriers. These data indicate the presence of altered immunity to the nucleocapsid antigens in these two types of chronic HBV carrier that are known to respond poorly to antiviral therapy.
慢性乙型肝炎病毒(HBV)携带者对干扰素治疗产生应答之前,会先出现IgM类抗-HBc(乙型肝炎核心抗原抗体)。IgM抗-HBc应答的时间关系和强度各不相同,这表明该抗体并非直接参与肝细胞裂解,而仅仅是干扰素诱导的对核衣壳蛋白免疫状态改变的一个标志物。治疗期间IgG 1、2、3和4没有变化。两名中国HBV携带者体内不存在所有亚类的IgG抗-HBc。在人类免疫缺陷病毒抗体阳性(抗-HIV)携带者中检测到抗-HBc滴度低于正常水平(P<0.001)。这些数据表明,在这两种已知对抗病毒治疗反应不佳的慢性HBV携带者中,存在对核衣壳抗原的免疫改变。